Literature DB >> 28914599

Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Jing Luo1, Brian S Johnston1, Averi E Kitsch1, Daniel S Hippe1, Larissa A Korde1, Sara Javid1, Janie M Lee1, Sue Peacock1, Constance D Lehman1, Savannah C Partridge1, Habib Rahbar1.   

Abstract

Purpose To investigate whether specific imaging features on breast magnetic resonance (MR) images are associated with ductal carcinoma in situ (DCIS) recurrence risk after definitive treatment. Materials and Methods Patients with DCIS who underwent preoperative dynamic contrast material-enhanced (DCE) MR imaging between 2004 and 2014 with ipsilateral recurrence more than 6 months after definitive surgical treatment were retrospectively identified. For each patient, a control subject with DCIS that did not recur was identified and matched on the basis of clinical, histopathologic, and treatment features known to affect recurrence risk. On DCE MR images, lesion characteristics (longest diameter, functional tumor volume [FTV], peak percentage enhancement [PE], peak signal enhancement ratio [SER], and washout fraction) and normal tissue features (background parenchymal enhancement [BPE] volume, mean BPE) were quantitatively measured. MR imaging features were compared between patients and control subjects by using the Wilcoxon signed-rank test, with adjustment for multiple comparisons. Results Of 415 subjects with DCIS who underwent preoperative MR imaging, 14 experienced recurrence and 11 had an identifiable matching control subject (final cohort, 11 patients and 11 control subjects). Median time to recurrence was 14 months, and median follow-up for control subjects was 102 months. When compared with matched control subjects, patients with DCIS recurrence exhibited significantly greater FTV (median, 9.3 cm3 vs 1.3 cm3, P = .01), lesion peak SER (median, 1.7 vs 1.2; P = .03), and mean BPE (median, 58.3% vs 41.1%; P = .02). Conclusion Quantitative lesion and normal breast tissue characteristics at preoperative MR imaging in women with newly diagnosed DCIS show promise for association with breast cancer recurrence after treatment. © RSNA, 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28914599      PMCID: PMC5708288          DOI: 10.1148/radiol.2017170587

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

1.  Selecting individualized treatment for patients with ductal carcinoma in situ of the breast: the search continues.

Authors:  Lawrence J Solin
Journal:  J Clin Oncol       Date:  2012-01-17       Impact factor: 44.544

2.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Authors:  Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

3.  Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery.

Authors:  Sun-Ah Kim; Nariya Cho; Eun Bi Ryu; Mirinae Seo; Min Sun Bae; Jung Min Chang; Woo Kyung Moon
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

4.  Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Authors:  Joann G Elmore; Gary M Longton; Patricia A Carney; Berta M Geller; Tracy Onega; Anna N A Tosteson; Heidi D Nelson; Margaret S Pepe; Kimberly H Allison; Stuart J Schnitt; Frances P O'Malley; Donald L Weaver
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

5.  Pathophysiologic basis of contrast enhancement in breast tumors.

Authors:  M V Knopp; E Weiss; H P Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; G Brix; S Delorme; I Zuna; G van Kaick
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

6.  Radiologic-pathologic correlation of ductal carcinoma in situ.

Authors:  Takayuki Yamada; Naoko Mori; Mika Watanabe; Izo Kimijima; Tadayuki Okumoto; Kazumasa Seiji; Shoki Takahashi
Journal:  Radiographics       Date:  2010-09       Impact factor: 5.333

7.  Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time?

Authors:  Sara L Jackson; Paul D Frederick; Margaret S Pepe; Heidi D Nelson; Donald L Weaver; Kimberly H Allison; Patricia A Carney; Berta M Geller; Anna N A Tosteson; Tracy Onega; Joann G Elmore
Journal:  Ann Surg Oncol       Date:  2016-12-02       Impact factor: 5.344

8.  Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ.

Authors:  Ann C Raldow; David Sher; Aileen B Chen; Abram Recht; Rinaa S Punglia
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

Review 9.  Standard for the management of ductal carcinoma in situ of the breast (DCIS).

Authors:  Monica Morrow; Eric A Strom; Lawrence W Bassett; D David Dershaw; Barbara Fowble; J a y R Harris; Frances O'Malley; Stuart J Schnitt; S Eva Singletary; David P Winchester
Journal:  CA Cancer J Clin       Date:  2002 Sep-Oct       Impact factor: 508.702

Review 10.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.

Authors:  Beth A Virnig; Todd M Tuttle; Tatyana Shamliyan; Robert L Kane
Journal:  J Natl Cancer Inst       Date:  2010-01-13       Impact factor: 13.506

View more
  11 in total

Review 1.  Background parenchymal enhancement on breast MRI: A comprehensive review.

Authors:  Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar
Journal:  J Magn Reson Imaging       Date:  2019-04-19       Impact factor: 4.813

Review 2.  Ductal Carcinoma in Situ: State-of-the-Art Review.

Authors:  Lars J Grimm; Habib Rahbar; Monica Abdelmalak; Allison H Hall; Marc D Ryser
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

3.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.

Authors:  Rossella Rella; Andrea Contegiacomo; Enida Bufi; Sara Mercogliano; Paolo Belli; Riccardo Manfredi
Journal:  Br J Radiol       Date:  2020-10-15       Impact factor: 3.039

5.  Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.

Authors:  Natsuko Onishi; Wen Li; David C Newitt; Roy J Harnish; Fredrik Strand; Alex Anh-Tu Nguyen; Vignesh Amal Arasu; Jessica Gibbs; Ella F Jones; Lisa J Wilmes; John Kornak; Bonnie N Joe; Elissa R Price; Haydee Ojeda-Fournier; Mohammad Eghtedari; Kathryn W Zamora; Stefanie Woodard; Heidi R Umphrey; Michael T Nelson; An L Church; Patrick J Bolan; Theresa Kuritza; Kathleen Ward; Kevin Morley; Dulcy Wolverton; Kelly Fountain; Dan Lopez Paniagua; Lara Hardesty; Kathleen R Brandt; Elizabeth S McDonald; Mark Rosen; Despina Kontos; Hiroyuki Abe; Deepa Sheth; Erin Crane; Charlotte Dillis; Pulin Sheth; Linda Hovanessian-Larsen; Dae Hee Bang; Bruce Porter; Karen Y Oh; Neda Jafarian; Luminita A Tudorica; Bethany Niell; Jennifer Drukteinis; Mary S Newell; Marina E Giurescu; Elise Berman; Constance D Lehman; Savannah C Partridge; Kimberly A Fitzpatrick; Marisa H Borders; Wei Tse Yang; Basak Dogan; Sally Hayward Goudreau; Thomas Chenevert; Christina Yau; Angela DeMichele; Donald A Berry; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2021-08-24       Impact factor: 29.146

6.  Harmonization of Quantitative Parenchymal Enhancement in T1 -Weighted Breast MRI.

Authors:  Bas H M van der Velden; Michael J van Rijssel; Beatrice Lena; Marielle E P Philippens; Claudette E Loo; Max A A Ragusi; Sjoerd G Elias; Elizabeth J Sutton; Elizabeth A Morris; Lambertus W Bartels; Kenneth G A Gilhuijs
Journal:  J Magn Reson Imaging       Date:  2020-06-03       Impact factor: 4.813

7.  Ipsilateral Recurrence of DCIS in Relation to Radiomics Features on Contrast Enhanced Breast MRI.

Authors:  Ga Eun Park; Sung Hun Kim; Eun Byul Lee; Yoonho Nam; Wonmo Sung
Journal:  Tomography       Date:  2022-03-01

8.  Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial).

Authors:  Shinn-Huey S Chou; Justin Romanoff; Constance D Lehman; Seema A Khan; Ruth Carlos; Sunil S Badve; Jennifer Xiao; Ralph L Corsetti; Sara H Javid; Derrick W Spell; Linda K Han; Jennifer L Sabol; John R Bumberry; Ilana F Gareen; Bradley S Snyder; Constantine Gatsonis; Lynne I Wagner; Antonio C Wolff; Kathy D Miller; Joseph A Sparano; Christopher E Comstock; Habib Rahbar
Journal:  Radiology       Date:  2021-08-03       Impact factor: 29.146

Review 9.  Application of Radiomics and Decision Support Systems for Breast MR Differential Diagnosis.

Authors:  Ioannis Tsougos; Alexandros Vamvakas; Constantin Kappas; Ioannis Fezoulidis; Katerina Vassiou
Journal:  Comput Math Methods Med       Date:  2018-09-23       Impact factor: 2.238

10.  Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.

Authors:  Alex Anh-Tu Nguyen; Vignesh A Arasu; Fredrik Strand; Wen Li; Natsuko Onishi; Jessica Gibbs; Ella F Jones; Bonnie N Joe; Laura J Esserman; David C Newitt; Nola M Hylton
Journal:  Tomography       Date:  2020-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.